OncoTherapy Science, Inc.
4564.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.19 | -0.80 | 0.14 | -0.09 |
| FCF Yield | -11.15% | -28.92% | -8.84% | -19.56% |
| EV / EBITDA | -8.04 | -2.98 | -7.27 | -5.45 |
| Quality | ||||
| ROIC | -96.69% | -221.18% | -122.88% | -98.72% |
| Gross Margin | -1.70% | -29.13% | 3.67% | 9.87% |
| Cash Conversion Ratio | 1.00 | 0.95 | 0.71 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | -12.89% | -19.13% | 50.57% | 53.94% |
| Free Cash Flow Growth | 33.75% | -53.77% | 68.37% | -40.06% |
| Safety | ||||
| Net Debt / EBITDA | 0.96 | 0.33 | 1.02 | 0.90 |
| Interest Coverage | -664.39 | -5,141.28 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 9.67 | 10.65 | 10.97 | 4.50 |
| Cash Conversion Cycle | 85.85 | 147.41 | 72.85 | 207.58 |